A study to compare the effectiveness and safety of bempedoic acid and ezetimibe for treating high lipid levels

A Comparative study to evaluate the efficacy and safety of Bempedoic acid versus Ezetimibe in patients with Dyslipidemia - NIL

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/07/070838

Enrollment

106

Registered

2024-07-18

Start date

Unknown

Completion date

Unknown

Last updated

2024-07-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E785- Hyperlipidemia, unspecified

Interventions

Intervention1: Bempedoic acid: Dose: 180 mg Frequency: OD (once a day) Route: Oral Duration: 12 weeks Control Intervention1: Ezetimibe: Dose: 10 mg Frequency: OD (once a day) Route: Oral Duration: 1

Eligibility

Inclusion criteria

Inclusion criteria: Stable atherosclerotic cardiovascular disease Uncontrolled LDL cholesterol level (fasting more than 70 mg/dl) on maximally tolerated dose of statin.(Atrovastatin 80 mg OD, Rosuvastatin 40 mg OD)

Exclusion criteria

Exclusion criteria: Age less than 18 yr BMI more or equal 40 kg/m sq. Triglyceride levels more or equal to 500 mg/dl History of statin intolerance History of cardiac event in last 12 weeks Pregnant and Lactating women.

Design outcomes

Primary

Measure	Time frame
Achieving the target level of fasting LDL-C less than 70 mg/dlTimepoint: 0 week 6 weeks 12 weeks	—

Secondary

Measure	Time frame
The study shall further examine the adverse drug reaction caused by Bempedoic acid 180 mg and Ezetimibe 10 mg in patients of dyslipidemia.Timepoint: 0,6,12th weeks	—

Countries

India

Contacts

Public ContactAfzal Noor

Eras Lucknow Medical College

dr.dilshadali@yahoo.com9450025751

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026